Dr. Julian A. Symons is the Exec. VP & Chief Scientific Officer at Aligos Therapeutics.
As the Exec. VP & Chief Scientific Officer of Aligos Therapeutics, the total compensation of Dr Symons at Aligos Therapeutics is $580,110. There are 4 executives at Aligos Therapeutics getting paid more, with Dr. Lawrence M. Blatt having the highest compensation of $900,082.
Dr Symons is 59, he's been the Exec. VP & Chief Scientific Officer of Aligos Therapeutics since . There are 10 older and 13 younger executives at Aligos Therapeutics. The oldest executive at Aligos Therapeutics, Inc. is Yair Keusch, 79, who is the External Director.
Julian's mailing address filed with the SEC is C/O ALIGOS THERAPEUTICS, INC., ONE CORPORATE DRIVE, 2ND FLOOR, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 4 years, insiders at Aligos Therapeutics have traded over $0 worth of Aligos Therapeutics stock and bought 9,083,601 units worth $23,279,537 . The most active insiders traders include Holdings A/S Novo, Carole Nuechterlein und Thomas Woiwode. On average, Aligos Therapeutics executives and independent directors trade stock every 220 days with the average trade being worth of $25,070,736. The most recent stock trade was executed by Carole Nuechterlein on 25 October 2023, trading 7,933,601 units of ALGS stock currently worth $6,029,537.
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company also develops ALG-020572, an antisense oligonucleotide to prevent HBsAg translation and secretion; and ALG-055009, a small molecule THR-ß agonist that is in the Phase 1a/1b for the treatment of non-alcoholic steatohepatitis(NASH). In addition, it develops siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, demonstrated potent inhibition of HBsAg release from HBV-infected cells. It has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; Emory University to provide hepatitis B virus capsid assembly modulator technology; research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors; and Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH. The company was incorporated in 2018 and is headquartered in South San Francisco, California.
Aligos Therapeutics executives and other stock owners filed with the SEC include: